Last reviewed · How we verify
Remimazolam Besylate for Injection — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Remimazolam Besylate for Injection (Remimazolam Besylate for Injection) — The First Affiliated Hospital of Xinxiang Medical College.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Remimazolam Besylate for Injection TARGET | Remimazolam Besylate for Injection | The First Affiliated Hospital of Xinxiang Medical College | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Remimazolam Besylate for Injection CI watch — RSS
- Remimazolam Besylate for Injection CI watch — Atom
- Remimazolam Besylate for Injection CI watch — JSON
- Remimazolam Besylate for Injection alone — RSS
Cite this brief
Drug Landscape (2026). Remimazolam Besylate for Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/remimazolam-besylate-for-injection. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab